Spero Therapeutics/$SPRO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Spero Therapeutics
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
- Ticker
- $SPRO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 25
- Headquarters
- Cambridge, United States
- Website
- sperotherapeutics.com
SPRO Metrics
BasicAdvanced
$59M
7.98
$0.13
1.48
-
Price and volume
Market cap
$59M
Beta
1.48
52-week high
$3.08
52-week low
$0.96
Average daily volume
421K
Financial strength
Current ratio
6.121
Quick ratio
6.027
Long term debt to equity
0.001
Total debt to equity
0.046
Profitability
Gross margin (TTM)
56.31%
Net profit margin (TTM)
15.71%
Operating margin (TTM)
14.07%
Effective tax rate (TTM)
3.41%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
7.19%
Return on equity (TTM)
19.17%
Valuation
Price to earnings (TTM)
7.983
Price to revenue (TTM)
1.237
Price to book
1.34
Price to tangible book (TTM)
1.34
Price to free cash flow (TTM)
2.968
Free cash flow yield (TTM)
33.69%
Free cash flow per share (TTM)
0.344
Growth
Revenue change (TTM)
-3.25%
Earnings per share change (TTM)
-113.10%
3-year revenue growth (CAGR)
-4.66%
3-year earnings per share growth (CAGR)
-15.59%
What the Analysts think about SPRO
Analyst ratings (Buy, Hold, Sell) for Spero Therapeutics stock.
Analyst projections of the future price of Spero Therapeutics stock.
SPRO Financial Performance
Revenues and expenses
SPRO Earnings Performance
Company profitability
Upcoming events
No upcoming events
SPRO News
AllArticlesVideos
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga2 weeks ago
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
MarketBeat3 weeks ago
Russian plague outbreak could boost these under-the-radar pharma stocks
Invezz1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.